1. Generics Bulletin
  2. >>Products
  3. >>Generics

Generics Bulletin Explains: The Changing US Generics Market

Price Pressures Are Abating Amid Portfolio Pruning, Market Exits And Shortages

 
• By Dave Wallace

After a couple of years of heavy downwards pressure on US generics prices, prominent off-patent companies have pointed to a change in the pricing environment as several factors combine to reduce price erosion. Meanwhile, some firms are benefiting from first generic launches as others exit the market altogether, while injectables shortages continue to loom large.

Dollar coin squeezed in G-clamp on top of USA flag
Pricing pressures on generic drugs are easing in the US • Source: Shutterstock

Robert Califf, commissioner of the US Food and Drug Administration, recently summarized in straightforward terms the disconnect between the public perception of high drug prices and the realities for the off-patent industry by stating that innovator prices “are too high,” while for the generics industry “a lot of the prices are too low.”

“What I mean by that,” Califf explained, in widely reported comments made at an Alliance for a Stronger FDA event,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

European Industry Calls For Support As It Juggles Multiple Challenges

 
• By Dave Wallace

At Medicines for Europe’s legal and annual conferences in Brussels last week, multiple key issues competed for attention, giving the generics and biosimilars industry plenty to think about at a critical time for EU pharma reform.

US Federal Circuit Says It Will Not Rehear Viatris Invega Trinza Infringement Ruling

 
• By Dean Rudge

The US Federal Circuit’s March 2025 decision affirming a lower court’s determination on both induced infringement and non-obviousness concerning a key patent shielding Janssen’s Invega Trinza (paliperidone palmitate) long-acting injectable is set to stand – for now.

FDA Will Not Pull Teva And MSN Hetlioz ANDAs, Finds No ‘Serious Discrepancies’

 
• By Dean Rudge

The FDA has concluded that generic tasimelteon products held by Teva and MSN Labs meet all statutory bioequivalence requirements, and that there was no “mistake” or untrue statement in the original ANDA approvals, as it denied Vanda’s citizen petition.

CivicaScript Offers Generic Tecfidera To US Pharmacies For $47 Per Bottle

 
• By Urtė Fultinavičiūtė

As CivicaScript continues its mission to make treatments more accessible with its newly launched generic Tecfidera at a low price, generic drug coverage remains under threat, showed AAM analysis.

More from Products

Bio Usawa To Market Formycon’s Lucentis Biosimilar In Sub-Saharan Africa

 
• By Urtė Fultinavičiūtė

Bio Usawa’s CEO said access to advanced biologics should not be a privilege of geography or income, as it prepares to launch Formycon/Bioeq’s ranibizumab biosimilar in Africa.

CivicaScript Offers Generic Tecfidera To US Pharmacies For $47 Per Bottle

 
• By Urtė Fultinavičiūtė

As CivicaScript continues its mission to make treatments more accessible with its newly launched generic Tecfidera at a low price, generic drug coverage remains under threat, showed AAM analysis.

Sandoz Starts Construction On $440m Slovenian Biosimilars Plant

 
• By Dave Wallace

Sandoz has begun constructing a major biosimilars manufacturing facility in Slovenia that is set to become operational in 2028. A $440m investment in the project adds to local biosimilars initiatives that together total over $1bn, helping Sandoz to move out of the shadow of former parent Novartis.